Addition Of Wee1 Inhibitor To Gemcitabine Reduces Risk Of Disease Progression And Death In Women With Recurrent, Platinum-Resistant Or -Refractory Ovarian Cancer In Phase 2 Trial

MedPage Today (1/25, Ingram) reports researchers found in a phase 2 trial that the addition of “the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer.” The trial’s results were published in The Lancet.